1	Randomized Phase 2 Trial of Lirilumab
2	as maintenance Treatment in Acute Myeloid Leukemia:
3	Results of the EFFIKIR Trial
1	
4	N $V_{12}^{4}$ AS $C_{12}^{4}$ DV $D_{12}^{2}$ $C_{12}^{4}$ $D_{12}^{4}$ D $L_{12}^{2}$ $C_{12}^{5}$ $C_{12}^{6}$ D $L_{12}^{1}$
3	N. Vey *, AS. Chretten *, PY. Dumas, C. Recher, L. Gastaud, B. Lioure, CE. Bulabois,
6	C.Pautas', JP.Marolleau <sup>8</sup> , S.Lepretre <sup>9</sup> , E.Raffoux <sup>10</sup> , X.Thomas <sup>11</sup> , Y.Hichri <sup>12</sup> , C.Bonmati <sup>13</sup> ,
7	B.Quesnel <sup>14</sup> , P.Rousselot <sup>15</sup> , E.Jourdan <sup>16</sup> , JV.Malfuson <sup>17</sup> , G.Guillerm <sup>18</sup> , JH.Bourhis <sup>19</sup> ,
8	M.Ojeda-Uribe <sup>20</sup> , M.Hunault <sup>21</sup> , A.Ben Amara <sup>1</sup> , MS.Rouvière <sup>1</sup> , N.Boucherit <sup>1</sup> , P.André <sup>22</sup> ,
9	C.Preudhomme <sup>14</sup> , N.Dulphy <sup>10</sup> , A.Toubert <sup>10</sup> , N. Ifrah <sup>21</sup> , D.Olive <sup>1</sup> *, and H.Dombret <sup>10</sup> *
10	
11	<sup>1</sup> Institut Paoli-Calmettes, Marseille, France; <sup>2</sup> CHU Bordeaux, Service d'Hématologie Clinique et de Thérapie
12	Cellulaire, F-33000, Bordeaux, France, <sup>3</sup> CHU Toulouse, Institut Universitaire du Cancer de Toulouse
13	Oncopole, France, <sup>4</sup> Centre Antoine Lacassagne, Nice, France, <sup>5</sup> CHU, Institut de CANcérologie de Strasbourg
14	Europe, ICANS, France, <sup>6</sup> CHU de Grenoble, France, <sup>7</sup> Hopital Henri Mondor, Créteil, France, <sup>8</sup> CHU Amiens,
15	France, <sup>9</sup> Centre Henri Becquerel, Rouen, France <sup>10</sup> Hôpital Saint Louis, Paris, France; <sup>11</sup> CHU Lyon Sud,
16	France, <sup>12</sup> CHU Montpellier, France, <sup>13</sup> CHU Nancy, France, <sup>14</sup> CHRU Lille, France, <sup>15</sup> CH de Versailles, France,
17	<sup>16</sup> CHU de Nîmes, France, <sup>17</sup> Hôpital Militaire Percy, Clamart, France, <sup>18</sup> CHU de Brest, France, <sup>19</sup> Institut
18	Gustave Roussy, Villejuif, France, <sup>20</sup> CH Mulhouse, France, <sup>21</sup> CHU Angers, France, <sup>22</sup> Innate Pharma, Marseille,
19	France.
20	
21	* Equally contributed to this work.
22	
23	
24 25	Correspondence and requests for materials should be addressed to Norbert Vey and Anne-Sophie Chretien.
26	Text word count: 3957
27	Abstract word count: 249
28	Number of figures: 5
29	Number of tables: 2
30	Numbers of supplementary figures: 4
31	Numbers of supplementary tables: 1
32	Number of references: 39
33	Chart (Mart 1) allowed in AMI - DEEUZID (al. 1
54	Snort utie: Lifilumad in ANIL: EFFIKIK trial

# 35 KEY POINTS

36 37	• Prolonged full KIR blockade leads to potentially deleterious effects on NK cells, CD8 <sup>+</sup> T cells and $v\delta2^+\gamma\deltaT$ cells
38 39	• Combined inhibitory effects of KIR blockade may have resulted in the impairment of immunosurveillance associated with high rate of relapse
40	
41	
42	
43	
44	
45	
46	

## 47 ABSTRACT

48 Lirilumab is a fully human monoclonal antibody designed to block killer inhibitory receptors 49 (KIR), which are major immune checkpoints involved in the regulation of NK cell-mediated 50 killing of HLA-I-expressing tumors. EFFIKIR is a multicenter randomized double-blind 3-51 arm placebo-controlled phase II trial with lirilumab as single-agent as maintenance therapy of 52 elderly patients with AML in first complete remission (NCT01687387). Two dose schedules 53 led to either continuous or intermittent KIR occupancy. 153 patients were randomized and 54 152 patients were treated after 3+7 induction therapy. The median follow-up was 36.6 55 months. Lirilumab was well tolerated, with no significant hematological toxicity. The median 56 LFS were 17.6, 6.7 and 13.9 months in the 0.1mg/kg arm, 1mg/kg arm and placebo arm, 57 respectively. An excess in early relapse led to early termination of treatment in the 1mg/kg arm. Extensive analysis of immune cell fate following KIR blockade evidenced a decrease of 58 59 KIR<sup>+</sup> NK cell absolute counts following KIR blockade, associated with a decrease of Bcl-2. 60 Lirilumab also bound antigen-experienced CD8<sup>+</sup> T cells, and induced a transient decrease of 61 CD69 expression. Besides, lirilumab bound  $v\delta^2 \gamma \delta T$  cells with a high cytotoxic potential, 62 and induced a decrease of DNAM-1 and Bcl-2, the latter being associated with a decrease of 63 KIR<sup>+</sup>  $\gamma \delta T$  cell, and with a drastic reduction of time to relapse. Overall, the potentially 64 deleterious effects on immune effectors may have resulted in the impairment of immune 65 surveillance associated with an unexpected high rate of early relapse in the group of patients 66 exposed to prolonged full KIR blockade.

### 67 **INTRODUCTION**

68 Killer cell Immunoglobulin-like Receptors (KIRs) are a class of major immune checkpoints that negatively regulate Natural Killer (NK) cell anti-tumor activity.<sup>1,2</sup> Inhibitory KIR, 69 70 KIR2DL and KIR3DL, display extracellular immunoglobulin-like domains conferring 71 specificity for HLA-C or HLA-A/B allotypes, respectively. Blockade of inhibitory NK 72 receptors has therefore the unique potential to enhance tumor cell killing without affecting 73 healthy tissues. NK cells are cytotoxic against malignant cells, including Acute Myeloid Leukemia (AML)<sup>1,3</sup>, and AML-induced NK cell alterations are associated with a poor 74 prognosis.<sup>4,5</sup> KIR blockade by IPH2101, an anti-KIR monoclonal antibody, was found to be 75 76 generally safe and displayed signals of activity in hematologic malignancies.<sup>6</sup> Lirilumab 77 (IPH2102/BMS-986015/BMS-986015-01) is a fully human IgG4 monoclonal antibody that 78 binds specifically and with high affinity to the main human inhibitory KIR, KIR2DL1 and 79 KIR2DL2/3. Lirilumab binding blocks the interaction of KIR2DL with HLA-C allotypes, 80 prevents inhibitory signals, and fosters activation NK cell activation. In a phase I study of 81 lirilumab in patients with hematological malignancies and solid tumors, we have shown that as for IPH2101, lirilumab was safe and well tolerated.<sup>7</sup> 82

AML in older patients is associated with a dismal prognosis. With conventional intensive chemotherapy, complete remission (CR) rates are comprised between 50% and 70% and the relapse rate is high after remission, which results in median leukemia-free survival (LFS) of about 12 months, median overall survival (OS) of 9 months and only 5-10% of patients are long-term survivors.<sup>8-12</sup> There is thus a need to develop effective maintenance strategies, and immunotherapies targeting NK cell represent attractive approaches.

89

In our previous phase I study of lirilumab<sup>7</sup>, we observed that different pharmacodynamic profiles where associated with lirilumab dose: a transient saturation with the lowest dose versus a sustained full saturation with higher doses (0.015mg/kg versus 0.3mg/kg and above in that study). Evidence has highlighted the importance of KIR receptors in NK cell maturation and education<sup>13,14</sup> and suggests that, in the clinic, transient KIR blockade might allow both the optimal activation of NK cells and the education of new NK cells towards the end of each treatment cycle when occupancy is reduced.

97 In order to evaluate the clinical efficacy of lirilumab and to determine the optimal dose-98 schedule, we designed a 3-arm phase II placebo-controlled study which compared the LFS of 99 elderly patients in first CR of AML treated with two dose-schedules of lirilumab or placebo. 100 A subset participated to a correlative study allowing for the double-blinded evaluation of the

101 functional and phenotypic changes induced by the 2 treatment arms compared to the control 102 group. The endpoints of the study were not met, and excess in early relapse led to early 103 termination of the study. Extensive analysis of the immune cell fate following KIR blockade 104 provides key elements to elucidate the potential mechanisms that led to this unexpected 105 excess of relapse despite inhibition of a major immune checkpoint.

106

107

108

## 109 PATIENTS AND METHODS

## 110 Study design and treatment

This is a prospective multicenter double-blinded phase II trial comparing two dose-schedules of Lirilumab to a placebo control administered in the maintenance therapy of elderly patients with AML in first CR following intensive chemotherapy. The study was conducted in 41 centers of the French ALFA and FILO cooperative groups.

115 Patients were randomized to one of the two treatment arms or placebo in a 1:1:1 ratio, with 116 minimization performed according to center, type of AML (primary versus secondary), 117 number of consolidation cycles (one versus two), and cytogenetics (high versus intermediate 118 risk). Lirilumab was administered at 0.1mg/kg every 12 weeks (arm A) or at 1mg/kg every 4 119 weeks (arm B) as a 1-hour IV infusion. Placebo (normal saline) was to be administered every 120 4 weeks as a 1-hour IV infusion in the placebo arm (arm C) and on weeks with no active 121 treatment in arm C, to ensure blinding. Patients were scheduled to receive 28-day cycles for 122 up to 24 months in the absence of intolerance or disease relapse. The study scheme is depicted 123 in Fig. 1. Lirilumab was provided by Innate Pharma (Marseille, France) as 5 mL vials 124 containing 10 mg/mL of lirilumab containing solution.

Study was approved by a national ethics committee (CPPRB) and registered at clinicaltrial.gov (NCT01687387).

127

### 128 Patients

Main study eligibility criteria were: patients with de novo or secondary AML defined according to World Health Organization 2008 criteria<sup>8</sup>, in first CR or CRi (according to the revised recommendations of the International Working Group<sup>15</sup>) achieved after one or two conventional induction chemotherapy and who had received one or two consolidation cycles. Two different anthracycline-cytarabine containing induction and consolidation regimens described in the Supplementary data section had been used as recommended by each

135 cooperative group. Induction chemotherapy had to have been administered within 6 months 136 before randomization and consolidation within 3 months following CR. Patient had to be non-137 eligible for an allogeneic hematopoietic stem cell transplantation (allo-HSCT), to be aged of 138 60 to 80 years, to have an Eastern Cooperative Oncology Group (ECOG) performance status 139 of 0 or 1; to have adequate renal and hepatic function. Patients with a history of auto-immune 140 disease, patients on steroids were not eligible. All patients gave written informed consent 141 prior to inclusion in the study.

142

#### 143 Efficacy and safety assessments

144 Safety was to be assessed, using Common Terminology Criteria for Adverse Events (CTCAE) 145 version 4.03. A safety analysis was performed every 6 months for safety assessment by the 146 DSMB. The primary efficacy variable for this trial was LFS, defined as the time elapsed 147 between randomization and the occurrence of disease relapse or death from any cause. 148 Secondary efficacy variables were the time to relapse (TTR), OS. TTR was defined as the 149 time elapsed between randomization and the occurrence of disease relapse; OS was the time 150 between randomization and death from any cause. Patients who had not progressed or died by 151 the time of the final analyses, were censored as of the date of last contact for calculation of 152 LFS, OS and TTR. Assessment of disease relapse was performed every 4 weeks during the treatment and during follow-up periods. Relapse was defined according to IWG criteria.<sup>15</sup> 153

154

### 155 Statistical analysis

156 The planned sample size for the study comprised 150 patients (i.e., 50 patients were to be 157 randomized to each treatment arm). This sample size was estimated in order to demonstrate a 158 hazard ratio (HR) for LFS of 0.6 in favor of maintenance therapy with an 80% power for a 159 one-sided log-rank test at an overall alpha level of 5%. The final sample size consisted of 169 160 screened patients, 153 randomized patients, and 152 treated patients. All efficacy analyses 161 were performed using data from the Intention-to-treat (ITT) Population, which consisted of all 162 subjects who received at least one dose of study medication. The Safety Population used for 163 the safety analyses consisted of all patients who received at least one dose of lirilumab.

Following a DSMB meeting held on 10 March 2015, a unanimous recommendation was made to stop further treatment for ongoing patients treated with lirilumab 1mg/kg due to an apparent excess of early relapses compared with the two other groups. It was decided to keep the same assumptions regarding the number of LFS events to be observed in these two

groups, i.e. 69 LFS events. Consequently, the primary efficacy analysis was performed on these two groups, with the alpha level decreased to 2.5% and the power to 55%.

170 LFS was analyzed using the log-rank test stratified by the following stratification factors, as 171 recorded in the randomization file: primary versus secondary AML, and cytogenetics (high 172 versus intermediate risk). The stratification factor "number of consolidation cycles (1 versus 173 2)" was not used in the log-rank test because there were too few patients in some 174 combinations of strata and the log-rank test failed in this situation.

175

#### 176 Mass cytometry

PBMC were collected at C1D1H0, C1D8, C4D1, C7D1 and end of study (EOS), and cryopreserved in 10% DMSO. Forty-three patients participated to this correlative study (12 in arm 0.1mg/kg, 16 in arm 1.0mg/kg and 15 in the control arm. A total of 141 samples were analyzed among which 39 were collected at C1D1H0, 35 at C1D8, 26 at C4D1, 18 at C7D1, and 23 at EOS. PBMCs were processed as previously described.<sup>5,16</sup> The detailed protocol is provided in appendix. Lymphocytes were exported for further analysis using opt-SNE<sup>17</sup>. Lirilumab-bound cells were identified using a metal-conjugated anti-IgG4 antibody.

104

185 186

### 187 **RESULTS**

## 188 Patient characteristics

189 Between November 2012 and July 2014, 169 patients were screened, 153 were randomized, 190 and 152 were treated (Table 1). One patient was not treated in the lirilumab 0.1mg/kg arm, 191 due to consent withdrawal before treatment initiation. The final numbers of patients were 50 192 in the lirilumab 0.1mg/kg arm, 51 in the lirilumab 1mg/kg arm, and 51 in the placebo arm 193 (Fig. 1A). No significant imbalances were seen across treatment arms. Median age was 70 194 years. One fourth of patients had a favorable European LeukemiaNet (ELN) 2010 genetic 195 subtype of AML. The median time since AML diagnosis was 4.8 month and 81% of patients 196 had received two consolidation cycles prior to inclusion.

197

## 198 Treatment

Following a Data and Safety Monitoring Board (DSMB) recommendation on 10 March 2015,

200 the decision was made to stop further treatment for ongoing patients treated with lirilumab

201 1mg/kg due to an apparent excess of early relapses compared with the two other groups. At

that time, recruitment had already been completed. As a result, exposure was greater in the
lirilumab 0.1mg/kg arm (median number of cycles of 16) and in the placebo arm (median
number of cycles of 11) as compared to the lirilumab 1mg/kg arm (median number of cycles
of 8).

Relapse (62.7%) was the main reason for discontinuation (52.9% from the 0.1mg/kg arm,
72.5% from the 1mg/kg arm, and 62.7% from the placebo arm), followed by adverse events
(AEs) (10.5%), withdrawal of consent, investigator's decision, and sponsor's decision (1.3%
each) (Fig. S1).

210

# 211 Efficacy results

212 Efficacy analysis concerned only the comparison between lirilumab 0.1mg/kg versus placebo 213 (Fig. 1). The study did not meet its primary endpoint, as no significant difference between 214 lirilumab 0.1mg/kg and placebo was seen (stratified LFS Hazard ratio (HR): 0.98 (95% 215 confidence interval [CI], 0.61 to 1.56, p=0.936). The median LFS were 17.6, 6.7 and 13.9 216 months in the 0.1mg/kg arm, 1mg/kg arm and placebo arm, respectively. Regarding the 217 comparison between lirilumab 1mg/kg and placebo, no statistically significant difference was 218 observed, but LFS in the lirilumab 1mg/kg arm was inferior to that in the placebo arm 219 (median LFS of 6.7 months, HR 0.95; 95% CI, 0.59 to 1.53; p=0.177) (Fig. 1B).

With regard to secondary efficacy endpoints, no significant differences were found in any of the comparisons which TTR times, median OS (31.3, 20.2 and 41.6 months in the 0.1mg/kg arm, 1mg/kg arm and placebo arm, respectively, p=0.602 and 0.058) (Fig. 1C).

No prognostic factor for LFS for the comparison between lirilumab 0.1mg/kg and placebo was seen. For the comparison of lirilumab 1mg/kg with placebo, the type of induction therapy (idarubicin vs daunorubicin) and the number of platelets at the time of inclusion (<100 vs  $\geq 100 \times 10^{9}$ /L) were identified in the Cox model as independent prognostic factors for LFS (HR=1.35 and 4.14, respectively). Results are summarized as Forest Plots displayed in Fig. S2A and S2B.

As previously mentioned, an excess in early relapse was observed and justified early termination of treatment in the 1mg/kg arm. Although LFS was not statistically different between arms, curves clearly show an early drop in LFS in this arm as compared to the 2 others.

- 233
- 234 Safety

235 Overall, 91.4% of patients had at least one treatment-emergent AE. The event rates (i.e. the

number of patients with AEs divided by the total drug exposure in months), was lower in the

lirilumab 0.1mg/kg arm than in the lirilumab 1mg/kg and the placebo arms. The most frequent

- AEs are presented in Table 2. Infusion-related reactions were the most frequent, did not reach
- a grade 4, while grade 3 reactions frequency was nearly identical in the three arms.

240 No significant hematological toxicity was seen in the 3 arms. Eighteen malignant tumors were

- reported in 14 patients. 75% of patients were in the lirilumab 0.1mg/kg arm. There were 3
- basal-cell carcinoma, and the other six neoplasms had each a maximum of one case. In the
- 243 other two arms combined, there were 3 myeloid malignancies, 6 solid tumors (including 2
- 244 basal cell carcinomas).

A total of 81 deaths were reported during the study: 26 in the lirilumab 0.1mg/kg arm, 32 in the lirilumab 1mg/kg arm, and 23 in the placebo arm. Nearly 85% of such deaths were attributed to disease progression across the three arms.

248

# 249 Pharmacokinetics and pharmacodynamics

PK-PD sampling was performed for the first 60 randomized patients. Intermittent full KIR
occupancy was observed with the dose of 0.1mg/kg every 3 months, with full KIR occupancy
lasting 7 days to 1 month for the majority of the patients. Long-term full KIR occupancy was
observed at the dose of 1mg/kg every 4 weeks (Fig. S3).

254

# 255 Immune modifications during treatment

256 Lirilumab was not immunogenic with 15 patients presenting Human Anti-Human Antibodies, 257 all with low titers. Of note, 9 out of the 15 positive patients tested positive at baseline and 258 5/15 patients were in the placebo arm (data not shown). Lirilumab-induced immune 259 modifications were then extensively analyzed by mass cytometry. For these experiments, we 260 used a metal-conjugated anti-IgG4 antibody in order to specifically identify lirilumab-bound immune cells (Fig. 2A). As expected, based on prior in vitro studies<sup>18</sup>, lirilumab bound KIR-261 262 expressing immune populations, including NK cells,  $V\gamma 9V\delta 2^+ \gamma \delta T$  cells, CD8<sup>+</sup> T cells, and to 263 a lesser extent CD4<sup>+</sup> T cells (Fig. 2B-C). Eight days after lirilumab injection, 26.0% and 264 25.8% of NK cells had bound lirilumab in the lirilumab 0.1 and lirilumab 1.0 arms, respectively (Fig. 2C). The frequency of lirilumab-bound V $\gamma$ 9V $\delta$ 2<sup>+</sup>  $\gamma\delta$ T cells was 12.3% and 265 266 8.2% in the lirilumab 0.1 and lirilumab 1.0 arms, respectively. The mean frequency of lirilumab-bound cells was below 6% for CD8<sup>+</sup> T cells, and below 1% for CD4<sup>+</sup> T cells in both 267 268 arms. The frequency of lirilumab-bound immune cells was significantly decreased by C4D1

in the lirilumab 0.1 arm, while maintained in the lirilumab 1.0 arm until the end of study (Fig.

- 270 2C).
- 271

272 The impact of lirilumab binding on NK cells was further characterized using dimensionality 273 reduction analysis. Since one of the main hypotheses retained to explain the lack of clinical 274 benefit of anti-KIR therapy in multiple myeloma was the potential interference with NK cell education and development<sup>19,20</sup>, we first focused on NK cell maturation profiles. Lirilumab 275 did not induce any phenotypical shift, even after prolonged administration, except a slight 276 decrease of CD56<sup>bright</sup> NK cells at end of study (Fig. 3A and Fig. S4A). Besides, we observed 277 278 a transient decrease of the cluster of KIR<sup>+</sup> NK cells in the lirilumab 0.1 arm, and a durable 279 decrease of this population in the lirilumab 1.0 arm (Fig. S4B). Analysis of absolute counts of 280 KIR<sup>+</sup> NK cells in both arms at C1D8 evidenced a weak to drastic decrease in 17 out of 20 281 patients treated with lirilumab compared with baseline, while this decrease was weak and 282 limited to 3 out of 12 patients in the placebo arm (Fig. 3B), confirming prior observations in 283 multiple myeloma<sup>19</sup>. This decrease of KIR<sup>+</sup> NK cells was concomitant with a transient 284 decrease at C1D8 of the anti-apoptotic protein Bcl-2 in the lirilumab 1.0 arm, a critical protein NK cell survival.<sup>21</sup> This decrease affected all the populations of NK cells, independently of 285 286 lirilumab binding (Fig. 3C), suggesting an indirect mechanism involved in the loss of Bcl-2 287 consecutive to KIR blockade. Although not significant, a similar trend was also observed in 288 the lirilumab 0.1 arm (Fig. 3C).

289

290 Lirilumab binding on  $CD8^+$  T cells did not induce any phenotypical shift (Fig. 4A), and did 291 not impact T cell maturation profiles (data not shown). Lirilumab spared naive (CD27<sup>+</sup> 292 CCR7<sup>+</sup> CD45RA<sup>+</sup> CD28<sup>+</sup>), central memory (CD27<sup>+</sup> CCR7<sup>+</sup> CD45RA<sup>-</sup>), and effector memory 293 (CD27<sup>-</sup> CCR7<sup>-</sup> CD45RA<sup>-</sup>) CD8<sup>+</sup> T cells, and preferentially bound antigen-experienced CD8<sup>+</sup> 294 T cells with a terminally differentiated profile (CD27<sup>-</sup> CCR7<sup>-</sup> CD45RA<sup>+</sup> CD28<sup>-</sup>). Most 295 lirilumab-bound CD8<sup>+</sup> T cells also expressed CD56 and CD16, a phenotypic hallmark of T 296 cells with NK cell-like functions, and enhanced TCR-independent/CD16-dependent degranulation potential.<sup>22,23</sup> These cells also expressed the long-term immunological memory 297 marker CD57<sup>24</sup> (Fig. 4A). Upon lirilumab binding, we observed a decreased expression of the 298 299 activation marker CD69, a key regulator of tumor-specific CD8<sup>+</sup> T cells differentiation.<sup>25</sup> This 300 decrease was significant in arm 1.0 at late time points (C7D1), specifically affected lirilumab-301 bound CD8<sup>+</sup> T cells, and spared lirilumab-free CD8<sup>+</sup> T cells (Fig. 4B). We further analyzed 302 the effect of lirilumab binding at early time points on paired samples between C1D8 and

303 C4D1. Lirilumab was found to induce heterogeneous inter-individual responses after binding 304 to CD8<sup>+</sup> T cells. In 4 out of 8 patients, lirilumab induced up-regulation of the key immune 305 checkpoints CTLA-4, PD-1, and BTLA, which was likely the consequence of a prior 306 activation, as evidenced by higher expression of CD25 (IL-2R), CD28, as well as the 307 inducible co-stimulatory receptors OX40 and 4-1BB (Fig. 4C). In these patients, we also 308 observed an increase of exhausted CD8<sup>+</sup> T cells characterized by co-expression of PD-1 and 309 TIGIT, two co-inhibitory receptors increased upon T cell activation.<sup>26</sup>

- 310 We next focused on  $v\delta 2^+ \gamma \delta T$  cells, a key population of anti-tumor cells with particular 311 relevance in the context of tumors with low mutational burden and high plasticity in MHC-I expression such as AML.<sup>27–30</sup> Lirilumab mainly bound  $v\delta 2^+ \gamma \delta T$  cells with a high cytotoxic 312 potential (CD8<sup>+</sup> CD56<sup>+</sup> CD57<sup>+</sup> CD16<sup>+</sup>) (Fig. 5A). The number of anti-IgG4<sup>+</sup>  $\gamma\delta T$  cells was 313 314 insufficient in most patients from arm 0.1 and prevented performing reliable measurements in 315 this group. Upon administration, lirilumab induced a transient decrease of DNAM-1 at C7D1 316 in arm 1.0, a critical receptor involved in cytotoxicity (Fig. 5B). Besides, we observed a 317 decrease of absolute counts of anti-IgG4<sup>+</sup>  $v\delta 2^+$   $\gamma\delta T$  cells between C1D8 et C4D1 in arm 1.0 318 (Fig. 5C). As for NK cells, depletion of lirilumab-bound  $v\delta 2^+ \gamma \delta T$  cells was associated with a 319 transient decrease of Bcl-2 at C1D8, affecting  $v\delta 2^+ \gamma \delta T$  cells independent of lirilumab binding 320 (Fig. 5B). The effect of lirilumab on Bcl-2 expression was not correlated with treatment 321 schedules, and some patients in arm 0.1 displayed marked decrease of Bcl-2 despite reduced 322 lirilumab dosing. We therefore performed a pooled analysis of both treatment arms according 323 to Bcl-2 expression among patients that relapsed before the end of study. Patients with LFS 324 above the median maintained a high frequency of Bcl-2<sup>+</sup>  $v\delta 2^+ \gamma \delta T$  cells at C4D1, in contrast 325 to patients with LFS below the median (Fig. 5D). Consistently, the frequency of Bcl-2<sup>+</sup>  $v\delta^{2+}$ 326  $\gamma\delta T$  cells was decreased in all patients with LFS<3mo, while the frequency of Bcl-2<sup>+</sup>  $v\delta 2^+$ 327  $\gamma\delta T$  cells was increased or stable in 8 out of 11 patients with LFS>3mo (Fig. 5E). In line, 328 patients with decreased Bcl-2 expression displayed shorter time to relapse than patients with 329 stable or increased Bcl-2 expression at C1D8 (Fig. 5E). The apparent recovery of Bcl-2 by 330 C4D1 (Fig. 5B) might therefore be artefactual and potentially biased by the fact that most 331 patients with loss of Bcl-2 between C1D0 and C1D8 display LFS<3mo. Taken together, these 332 results highlight a potential link between loss of Bcl-2 in  $v\delta 2^+ \gamma \delta T$  cells consecutive to KIR 333 blockade and early relapse in patients treated with lirilumab.
- 334

#### 335 **DISCUSSION**

336 The current randomized phase II trial failed to meet its primary objective of demonstrating the 337 efficacy of lirilumab given as maintenance therapy in elderly patients in first CR from AML. 338 The primary endpoint, LFS, did not differ significantly between either of the lirilumab arms 339 and placebo arm, and there were no statistically significant differences in the secondary 340 efficacy endpoints of TTR and OS. However, the lirilumab 0.1mg/kg arm was associated with 341 a non-significant trend toward a higher LFS as compared to the placebo arm (17.6 versus 13.9 342 months) while an inverse trend was seen in the lirilumab 1mg/kg arm. The latter was stopped 343 early upon a DSMB decision due to the observation of a high rate of early relapse, which 344 translated into a shorter median OS (p=0.058).

345 We were not able to identify confounding factors which may explain the differences between 346 the 2 lirilumab arms. These include clinical and biological classical AML prognostic factors 347 such as the number of induction courses to achieve a CR, cytogenetics, and ELN genetic risk 348 classification. However, important parameters such as the level of minimal residual disease at 349 inclusion could not be assessed. Doses of 0.1mg/kg of lirilumab were associated with full but 350 transient KIR saturation on NK cells while 1mg/kg dose every 4 weeks led to continuous 351 saturation. However, it must be noted that substantial inter-patient variability was observed 352 and that some patients in the low dose arm actually achieved continuous full KIR saturation.

353

354 In order to decipher the mechanism involved in the excess of early relapse observed, we 355 developed mass cytometry panels to track lirilumab-bound cells during the course of 356 treatment, and dissect its impact on immune cell fate. We evidenced a decrease of KIR<sup>+</sup> NK 357 cell absolute counts following KIR blockade, confirming the results of the phase II trial assessing lirilumab in multiple myeloma.<sup>19</sup> One hypothesis retained to explain the lack of 358 359 clinical benefit of anti-KIR therapy in this setting was the potential interference with NK cell maturation homeostasis<sup>20</sup>, the latter being critical in AML as recently evidenced by our 360 361 group.<sup>5</sup> We failed to evidence maturation defects following lirilumab administration. Rather, 362 we evidenced a decrease of Bcl-2, a downstream target of IL-15 signaling, involved in mitochondrial apoptosis, autophagy and senescence.<sup>31–33</sup> The ability of lirilumab to target T 363 cells was notable, confirming prior pre-clinical observations.<sup>18</sup> Lirilumab preferentially bound 364 antigen-experienced CD8<sup>+</sup> T cells, leading to a transient decreased activation. The impact of 365 366 lirilumab on the  $v\delta 2^+ \gamma \delta T$  cell compartment was marked by a decreased expression of 367 DNAM-1 and Bcl-2, the latter being associated with a decrease of the absolute counts of KIR<sup>+</sup> 368  $\gamma \delta T$  cell, echoing previous work showing that inhibitory KIR (iKIR) expression on human T

369 cells is associated with higher levels of Bcl-2, and that blocking the iKIR-HLA interaction significantly decreased the count of live T cells<sup>34,35</sup>. Similar observations have also been 370 371 reported in the context of renal cell carcinoma: blocking the interaction of KIR/HLA-Cw4 372 resulted in the restoration of tumor-induced cell death following activation by interfering with 373 two proximal events of Fas signaling pathway, a sustained c-FLIP-L induction and a decrease in caspase 8 activity.<sup>36</sup> In line, recent work showed that KIR/HLA interactions extend lifespan 374 of human CD8<sup>+</sup> T cells.<sup>37</sup> Although no confirmation of such mechanisms has been reported in 375 376  $\gamma\delta T$  cells, we can speculate that similar mechanisms triggering cell death are engaged 377 following KIR blockade on these cells, the latter point requiring dedicated mechanistic 378 studies. Finally, this loss of Bcl-2 was associated with a drastic reduction of time to relapse. 379 Given the strong correlation between Bcl-2 expression by  $\gamma\delta T$  cells, CD8<sup>+</sup> T cells and NK 380 cells, we cannot exclude a cumulative negative effect of Bcl-2 down-regulation on these three 381 main anti-leukemic populations. However, these results extend the list of arguments in favor 382 of the central role of  $\gamma\delta T$  cells in the control of leukemic blast proliferation.

In conclusion, this study failed to demonstrate that lirilumab can prolong CR duration. In addition, we observed potentially deleterious effects on various immune effectors. These effects - which have not been previously reported - suggest that combined inhibitory effects may have resulted in the impairment of immune surveillance associated with an unexpected high rate of early relapse in the group of patients exposed to prolonged full KIR blockade. The results also confirm the importance of  $\gamma \delta T$  cells in the control of AML cells opening new avenues for future immunotherapeutic strategies.<sup>38,39</sup>

390 Overall, this study underlies the need to closely monitor the consequences of therapeutic 391 monoclonal antibodies binding on immune populations that appear minor in absolute number, 392 especially when these cells play a key role in tumor clearance. It also warns against the 393 possibility that immune interventions be associated with narrow therapeutic windows.

394

395

# **Competing interests**

P.A. is an employee and a shareholder of Innate Pharma. D.O. is the co-founder and ashareholder of Incheck therapeutics, Emergence therapeutics, and Alderaan Biotech.

## **399** Author contribution statement

- 400 N.V. and H.D. designed the research. N.V., H.D., P.A., A.S.C., A.T., N.D., and D.O. designed 401 the ancillary study. N.V. and A.S.C analyzed the data and drafted the article. N.V., C.R., L.G.,
- 401 the alchary study. N.V. and A.S.C analyzed the data and drafted the article. N.V., C.K., E.G. 402 B.L., C.E.B, C.P., J.P.L, S.L., E.R., E.R., X.T., Y.H., C.B., B.C., P.R., J.V.M, G.G., J.H.B.,
- 402 B.E., C.E.B., C.F., J.F.L, S.L., E.K., E.K., A.T., T.H., C.B., B.C., F.K., J.V.M, O.G., J.H. 403 M.O.U., M.H., C.P., N.I., and H.D. recruited patients, conducted patient follow-up, and
- 404 collected clinical data. A.B.A., N.B. and M.S.R. designed the mass cytometry panels and
- 405 performed the mass cytometry experiments. All authors revised and approved the manuscript.
- 405 performed the mass cytometry experiments. An authors revised and approved the manuscrip 406

# 407 **REFERENCES**

- 408
- 409 1. Caligiuri, M. A. Human natural killer cells. *Blood* **112**, 461–469 (2008).
- 410
  2. Bryceson, Y. T., March, M. E., Ljunggren, H.-G. & Long, E. O. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. *Blood* 107, 159–166 (2006).
- 412 3. Caligiuri, M. A., Velardi, A., Scheinberg, D. A. & Borrello, I. M. Immunotherapeutic approaches for 413 hematologic malignancies. *Hematology Am Soc Hematol Educ Program* 337–353 (2004) 414 doi:10.1182/asheducation-2004.1.337.
- 4. Fauriat, C. *et al.* Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. *Blood* 109, 323–330 (2007).
- 5. Chretien, A.-S. *et al.* High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. *Proc. Natl. Acad. Sci. U.S.A.* 118, e2020459118 (2021).
- 420
  6. Vey, N. *et al.* A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. *Blood*421
  120, 4317–4323 (2012).
- 422 7. Vey, N. *et al.* A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. *Oncotarget* 9, 17675–17688 (2018).
- 425
  426
  8. Vardiman, J. W. *et al.* The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood* 114, 937–51 (2009).
- 427
  428
  428
  428
  429
  429
  429
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
  420
- 430
  431
  431
  432
  433
  434
  434
  435
  435
  435
  436
  436
  436
  437
  437
  438
  438
  439
  439
  439
  430
  430
  431
  431
  431
  432
  431
  432
  431
  432
  431
  432
  431
  432
  431
  432
  431
  432
  431
  432
  431
  432
  431
  432
  431
  432
  431
  432
  431
  432
  431
  432
  431
  432
  431
  432
  432
  431
  432
  432
  432
  431
  432
  431
  432
  431
  432
  432
  432
  432
  432
  433
  433
  434
  434
  434
  435
  435
  435
  435
  436
  437
  437
  438
  438
  438
  439
  431
  432
  431
  432
  432
  432
  433
  434
  434
  434
  435
  435
  435
  436
  436
  437
  437
  438
  438
  438
  438
  438
  438
  439
  431
  431
  432
  432
  431
  432
  432
  432
  433
  433
  434
  434
  434
  434
  434
  435
  434
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
  435
- 433 11.Büchner, T. *et al.* Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia:
  434 A Study by the German Acute Myeloid Leukemia Cooperative Group. *JCO* 27, 61–69 (2009).
- 435
  435 12.Löwenberg, B. *et al.* Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. *Blood* 115, 2586–2591 (2010).
- 437 13. Anfossi, N. *et al.* Human NK cell education by inhibitory receptors for MHC class I. *Immunity* 25, 331–42 (2006).
- 439 14.Fauriat, C. *et al.* Estimation of the size of the alloreactive NK cell repertoire: studies in individuals
  440 homozygous for the group A KIR haplotype. *J Immunol* 181, 6010–9 (2008).
- 15. Cheson, B. D. *et al.* Revised recommendations of the International Working Group for Diagnosis,
  Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials
  in Acute Myeloid Leukemia. *Journal of clinical oncology* □: *official journal of the American Society of Clinical Oncology* 21, 4642–9 (2003).
- 445 16.Ben Amara, A. *et al.* High-throughput mass cytometry staining for deep phenotyping of human natural killer
  446 cells. *STAR Protoc* 3, 101768 (2022).
- 447
   448
   17.Belkina, A. C. *et al.* Automated optimized parameters for T-distributed stochastic neighbor embedding improve visualization and analysis of large datasets. *Nat Commun* 10, 5415 (2019).
- 18. Romagné, F. *et al.* Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells. *Blood* 114, 2667–2677 (2009).
- 451 19. Carlsten, M. *et al.* Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces
  452 Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma. *Clinical Cancer Research* 22, 5211–5222 (2016).
- 454 20.Sanchez-Correa, B. *et al.* Modulation of NK cells with checkpoint inhibitors in the context of cancer
   455 immunotherapy. *Cancer Immunol Immunother* 68, 861–870 (2019).

- 456 21.Malamut, G. *et al.* IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a
   457 potential new target in celiac disease-associated inflammation and lymphomagenesis. *J Clin Invest* 120,
- 458 2131–2143 (2010).
- 459 22. Björkström, N. K. *et al.* Elevated Numbers of FcγRIIIA+ (CD16+) Effector CD8 T Cells with NK Cell-Like
   460 Function in Chronic Hepatitis C Virus Infection. *The Journal of Immunology* 181, 4219–4228 (2008).
- 461 23.Georg, P. *et al.* Complement activation induces excessive T cell cytotoxicity in severe COVID-19. *Cell* 185, 493-512.e25 (2022).
- 463 24.Ahmed, R. et al. CD57+ Memory T Cells Proliferate In Vivo. Cell Rep 33, 108501 (2020).
- 464 25.Koyama-Nasu, R. *et al.* CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes.
   465 *Cancer Immunol Res* 11, 1085–1099 (2023).
- 26.Banta, K. L. *et al.* Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co blockade to optimize anti-tumor CD8+ T cell responses. *Immunity* 55, 512-526.e9 (2022).
- 468
   469
   27. Mensurado, S., Blanco-Domínguez, R. & Silva-Santos, B. The emerging roles of γδ T cells in cancer immunotherapy. *Nat Rev Clin Oncol* 20, 178–191 (2023).
- 470 28. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. *Science* 348, 69–74 (2015).
- 471 29. Christopher, M. J. *et al.* Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. *N Engl J* 472 *Med* 379, 2330–2341 (2018).
- 30. Toffalori, C. *et al.* Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. *Nat Med* 25, 603–611 (2019).
- 475 31.Chong, S. J. F. *et al.* Noncanonical Cell Fate Regulation by Bcl-2 Proteins. *Trends Cell Biol* 30, 537–555 (2020).
- 477 32.Czabotar, P. E. & Garcia-Saez, A. J. Mechanisms of BCL-2 family proteins in mitochondrial apoptosis. *Nat Rev Mol Cell Biol* 24, 732–748 (2023).
- 33.Ma, S., Caligiuri, M. A. & Yu, J. Harnessing IL-15 signaling to potentiate NK cell-mediated cancer
   immunotherapy. *Trends Immunol* 43, 833–847 (2022).
- 481 34.Boelen, L. *et al.* Inhibitory killer cell immunoglobulin-like receptors strengthen CD8 <sup>+</sup> T cell-mediated control of HIV-1, HCV, and HTLV-1. *Sci. Immunol.* 3, eaao2892 (2018).
- 35. Young, N. T., Uhrberg, M., Phillips, J. H., Lanier, L. L. & Parham, P. Differential Expression of Leukocyte
  Receptor Complex-Encoded Ig-Like Receptors Correlates with the Transition from Effector to Memory CTL. *The Journal of Immunology* 166, 3933–3941 (2001).
- 36.Gati, A. *et al.* CD158 receptor controls cytotoxic T-lymphocyte susceptibility to tumor-mediated activation induced cell death by interfering with Fas signaling. *Cancer Res* 63, 7475–7482 (2003).
- 37.Zhang, Y. *et al.* KIR-HLA interactions extend human CD8+ T cell lifespan in vivo. *Journal of Clinical Investigation* 133, e169496 (2023).
- 490 38.Cano, C. E. *et al.* BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells. *Cell Rep* 36, 109359 (2021).
- 39. De Gassart, A. *et al.* Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T
   cell-mediated antitumor immune response. *Sci Transl Med* 13, eabj0835 (2021).
- 494
- 495 496

## **Table 1:** Patient characteristics

	1 mg/kg Q4W	0.1 mg/kg Q12W	Placebo Q4W	
	N=51 (100%)	N=50 (100%)	N=51 (100%)	
Median age years (range)	70 (60-80)	70 (60-80)	69 (60-77)	
Sex (Female)	28 (55%)	16 (32%)	17 (33%)	
ECOG				
0	28 (55%)	27 (54%)	35 (69%)	
1	23 (45%)	23 (46%)	16 (31%)	
Secondary AML	6 (12%)	9 (18%)	7 (14%)	
ELN 2010 risk category				
- Favorable	15 (29%)	12 (24%)	12 (24%)	
- Intermediate-1/2	25 (49%)	27 (54%)	26 (51%)	
- Adverse	5(10%)	6 (12%)	5 (10%)	
Prior therapy				
- Induction (1 cycle / 2 cycles)	50 (98%) / 1 (2%)	50 (100%) / 0	48 (94%) / 3 (6%)	
- Consolidation (1 cycle / 2 cycles)	10 (20%) / 41 (80%)	9 (18%) / 41 (82%)	10 (20%) / 41 (80%)	
- Consolidation (1+5 / IDAC)	28 (55%) / 23 (45%)	20 (40%) / 29 (58%)	32 (63%) / 19 (37%)	
Median months since CR (range)	3.0 (1.1-5.0)	3.3 (1.3-5.5)	3.3 (2.0-5.9)	

# **Table 2:** Adverse events occurring in >10% of patients

# 

	Lirilumab		Lirilumab					
	1 mg/kg	Q4W	0.1 mg/kg Q12W		Placebo Q4W		Total	
	(N =51)		(N = 50)		(N=51)		(N = 152)	
	All	Grade	All	Grade	All	Grade	All	Grade
	grades	3 or 4	grades	3 or 4	grades	3 or 4	grades	3 or 4
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Any AE	48 (84)	15(29)	49 (98)	28 (56)	47 (92)	14 (29)	139 (91)	58 (38)
Asthenia	14 (28)	1 (2)	14 (28)	1(2)	14 (28)	0	42 (28)	2 (1)
Bronchitis	6 (12)	0	17 (34)	0	14 (28)	0	37 (24)	0
Pruritus	8 (16)	0	10 (20)	0	7 (14)	0	25 (16)	0
Thrombocytopenia	9 (18)	3 (6)	7(14)	4 (8)	3 (6)	2 (4)	19 (13)	9 (6)
Diarrhea	8 (16)	1 (2)	6 (12)	0	2 (4)	0	16 (11)	1(1)
Back pain	3 (6)	0	6 (12)	0	7(14)	0	16 (11)	0
Arthralgia	4 (8)	1 (2)	6 (12)	0	5 (10)	0	15 (10)	1(1)
Headache	8 (16)	0	4 (8)	0	3(10)	0	15 (10)	0
Pyrexia	6 (12)	0	4 (8)	0	5 (10)	0	15 (10)	0

## 505 Figure legends

506

507 Figure 1: Clinical outcome in patients treated with lirilumab 1.0 mg/kg, lirilumab 0.1
508 mg/kg or placebo. A: Study design. B: Primary endpoint: Leukemia-Free Survival. C:
509 Secondary endpoint : Overall Survival.

510

511 Figure 2: Distribution of lirilumab binding on immune populations. PBMC from patients 512 in arm 0.1 mg/kg (N=12), arm 1.0 mg/kg (N=16) and control arm (N=15) were collected at 513 C1D1H0, C1D8, C4D1, C7D1 and EOS and phenotyped by mass cytometry. A: Lirilumab-514 bound cells were identified using metal-conjugated an  $\alpha$ -IgG4 antibody. B: Consensus files 515 were generated using fixed number of  $\alpha IgG4+$  cells from each .fcs file, and projected on a t-516 SNE map. C: Frequency of  $\alpha IgG4+$  cells by treatment arm and by time point of blood 517 collection among CD4+ T cells, CD8+ T cells, V $\delta$ 2+  $\gamma\delta$ T cells, and NK cells. Data were 518 analyzed using a Kruskal-Wallis test followed by a Dunn's post test. \*P < 0.05; \*\*P < 0.01; 519 \*\*\*P < 0.001; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; C1D8: cycle 1 day 8; C4D1: 520 cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study.

521

522 Figure 3 : Impact of lirilumab on NK cells. A: Total peripheral NK cells were manually 523 pregated and exported for t-SNE analysis. Consensus files of  $\alpha$ IgG4+ NK cells were 524 generated with fixed number of cells for each treatment arm at each time point in order to 525 obtain a representative and balanced view of all patient groups. Consensus files were then 526 projected on t-SNE plots of total NK cells. B: Variations of absolute counts of KIR+ NK cells 527 between baseline and C1D8. C: Bcl-2 expression by treatment arm and by time point of blood 528 collection. C1D1H0 were pre-gated on KIR+ NK cells. C1D8 to EOS were pre-gated on 529 KIR+ cells for placebo arm. C1D8 to EOS were pre-gated on  $\alpha$ IgG4+ NK cells for arms A 530 and B. Paired samples were analyzed using a Wilcoxon matched-pairs signed rank test. For 531 multiple comparisons, data were analyzed using a Kruskal-Wallis test followed by a Dunn's 532 post test, and presented as interquartile ranges, median, and whiskers from minimum to maximum. \*P < 0.05; \*\*P < 0.01; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; C1D8: 533 534 cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study; PCB: placebo.

535

**Figure 4: Impact of lirilumab on CD8+ T cells.** A: Total peripheral CD8+ T cells were manually pregated and exported for t-SNE analysis. Consensus files of  $\alpha$ IgG4+ CD8+ T cells were generated with fixed number cells for each treatment arm at each time point. Consensus

539 files were then projected on t-SNE plots of total CD8+ T cells. B: CD69 expression by 540 treatment arm and by time point of blood collection. C: Variations of T cell triggering 541 receptors, immune checkpoints and activation markers expression between C1D8 and C4D1. 542 Paired samples from patients included in 1.0 arm were analyzed using hierarchical clustering. 543 For multiple comparisons, data were analyzed using a Kruskal-Wallis test followed by a 544 Dunn's post test, and presented as interquartile ranges, median, and whiskers from minimum 545 to maximum. \*P < 0.05; \*\*P < 0.01; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; 546 C1D8: cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study.

547

548 Figure 5 : Impact of lirilumab on v $\delta 2$ +  $\gamma \delta T$  cells. A: Total peripheral v $\delta 2$ +  $\gamma \delta T$  cells were 549 manually pregated and exported for t-SNE analysis. Consensus files of  $\alpha IgG4 + v\delta 2 + \gamma \delta T$ 550 cells were generated with fixed number cells for each treatment arm at each time point. 551 Consensus files were then projected on t-SNE plots of total  $v\delta 2+\gamma\delta T$  cells. B: DNAM-1 and 552 Bcl-2 expression by treatment arm and by time point of blood collection. C1D1H0 were pre-553 gated on KIR+ NK cells. C1D8 to EOS were pre-gated on KIR+ cells for placebo arm. C1D8 554 to EOS were pre-gated on  $\alpha$ IgG4+ NK cells for arms A and B. C: variations of absolute 555 counts of  $\alpha IgG4 + v\delta 2 + \gamma\delta T$  cells during the cours of treatment. D: Bcl-2 expression at C1D8 556 according to LFS. E: Variations of Bcl-2 expression between C1D1H0 and C1D8 according 557 to LFS (upper and middle panels). Time to relapse according to Bcl-2 variations between 558 C1D1H0 and C1D8 (lower panel). For multiple comparisons, data were analyzed using a 559 Kruskal-Wallis test followed by a Dunn's post test, and presented as interquartile ranges, 560 median, and whiskers from minimum to maximum. Paired samples were analyzed using a 561 Wilcoxon matched-pairs signed rank test. Comparison between two groups were performed 562 using a Mann–Whitney U test. \*P < 0.05; \*\*P < 0.01; ns, nonsignificant. C1D1H0: cycle 1 563 day 1 hour 0; C1D8: cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of 564 study; LFS: leukemia-free survival; PCB: placebo.

- 565
- 566
- 567





Placebo Q4W0.1 mg/kg Q12W1 mg/kg Q4W

С



**Figure 1: Clinical outcome in patients treated with lirilumab 1.0 mg/kg, lirilumab 0.1 mg/kg or placebo.** A: Study design. B: Primary endpoint: Leukemia-Free Survival. C: Secondary endpoint : Overall Survival.



Figure 2: Distribution of lirilumab binding on immune populations. PBMC from patients in arm 0.1 mg/kg (N=12), arm 1.0 mg/kg (N=16) and control arm (N=15) were collected at C1D1H0, C1D8, C4D1, C7D1 and EOS and phenotyped by mass cytometry. A: Lirilumab-bound cells were identified using metal-conjugated an α-IgG4 antibody. B: Consensus files were generated using fixed number of αIgG4+ cells from each .fcs file, and projected on a t-SNE map. C: Frequency of αlgG4+ cells by treatment arm and by time point of blood collection among CD4+ T cells, CD8+ T cells, Vδ2+ γδT cells, and NK cells. Data were analyzed using a Kruskal-Wallis test followed by a Dunn's post test. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; C1D8: cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study.



С

**Figure 3 : Impact of lirilumab on NK cells.** A: Total peripheral NK cells were manually pregated and exported for t-SNE analysis. Consensus files of  $\alpha$ lgG4+ NK cells were generated with fixed number of cells for each treatment arm at each time point in order to obtain a representative and balanced view of all patient groups. Consensus files were then projected on t-SNE plots of total NK cells. B: Variations of absolute counts of KIR+ NK cells between baseline and C1D8. C: Bcl-2 expression by treatment arm and by time point of blood collection. C1D1H0 were pre-gated on KIR+ NK cells. C1D8 to EOS were pre-gated on  $\alpha$ lgG4+ NK cells for arms A and B. Paired samples were analyzed using a Wilcoxon matched-pairs signed rank test. For multiple comparisons, data were analyzed using a Kruskal-Wallis test followed by a Dunn's post test, and presented as interquartile ranges, median, and whiskers from minimum to maximum. \**P* < 0.05; \*\**P* < 0.01; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; C1D8: cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study; PCB: placebo.





% CD69+ / αlgG4- CD8 T cells

Arm A

0.1 mg/kg



of αlgG4+ CD8+ T cells

Arm B

1 mg/kg



High

density

Low density













**Pregated on** KIR+/ $\alpha$ IgG4+ CD8+ T cells



C1D8 vs C4D1 (% variation)



Α

tSNE2

В

С

Figure 4: Impact of lirilumab on CD8+ T cells. A: Total peripheral CD8+ T cells were manually pregated and exported for t-SNE analysis. Consensus files of αlgG4+ CD8+ T cells were generated with fixed number cells for each treatment arm at each time point. Consensus files were then projected on t-SNE plots of total CD8+ T cells. B: CD69 expression by treatment arm and by time point of blood collection. C: Variations of T cell triggering receptors, immune checkpoints and activation markers expression between C1D8 and C4D1. Paired samples from patients included in 1.0 arm were analyzed using hierarchical clustering. For multiple comparisons, data were analyzed using a Kruskal-Wallis test followed by a Dunn's post test, and presented as interquartile ranges, median, and whiskers from minimum to maximum. \*P < 0.05; \*\*P < 0.01; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; C1D8: cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study.



**Figure 5 : impact of lirilumab on v\delta2+ v\deltaT cells.** A: Total peripheral v $\delta$ 2+ v $\delta$ T cells were manually pregated and exported for t-SNE analysis. Consensus files of  $\alpha$ lgG4+ v $\delta$ 2+ v $\delta$ T cells were generated with fixed number cells for each treatment arm at each time point. Consensus files were then projected on t-SNE plots of total v $\delta$ 2+ v $\delta$ T cells. B: DNAM-1 and Bcl-2 expression by treatment arm and by time point of blood collection. C1D1H0 were pre-gated on KIR+ NK cells. C1D8 to EOS were pre-gated on KIR+ cells for placebo arm. C1D8 to EOS were pre-gated on  $\alpha$ lgG4+ NK cells for arms A and B. C: variations of absolute counts of  $\alpha$ lgG4+ v $\delta$ 2+ v $\delta$ T cells during the cours of treatment. D: Bcl-2 expression at C1D8 according to LFS. E: Variations of Bcl-2 expression between C1D1H0 and C1D8 according to LFS (upper and middle panels). Time to relapse according to Bcl-2 variations between C1D1H0 and C1D8 (lower panel). For multiple comparisons, data were analyzed using a Kruskal-Wallis test followed by a Dunn's post test, and presented as interquartile ranges, median, and whiskers from minimum to maximum. Paired samples were analyzed using a Wilcoxon matched-pairs signed rank test. Comparison between two groups were performed using a Mann–Whitney *U* test. \**P* < 0.05; \*\**P* < 0.01; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; C1D8: cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study; LFS: leukemia-free survival; PCB: placebo.